Oltipraz - Canopus BioPharma

Drug Profile

Oltipraz - Canopus BioPharma

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Wisconsin-Madison
  • Developer Canopus BioPharma
  • Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules; Sulfhydryl compounds
  • Mechanism of Action DNA repair enzyme stimulants; Glutathione transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer; Mucositis

Most Recent Events

  • 23 Jun 2008 Canopus receives approval from the South African Medicines Control Council to begin a phase II trial with CB 1400 as a mucositis protective agent in patients with cancer
  • 19 Jun 2008 Preclinical trials in Cancer in USA (PO)
  • 19 Jun 2008 Preclinical pharmacodynamics data released by Canopus BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top